Director John Christopher “J.C.” Rozendaal was mentioned as representing Teva Pharmaceuticals in the article “Teva to Defend Ruling Allowing Narcan Generic at Federal Circuit,” published by Bloomberg Law. From the article:

“Adapt Pharma Inc.’s four patents on Narcan spray for treating opioid overdoses were properly invalidated because their components had been widely used for decades, Teva Pharmaceuticals USA Inc. will tell the Federal Circuit at oral argument.

The ruling from the U.S. District Court for the District of New Jersey paved the way for drug companies like Teva to make generic versions of Narcan. A three-judge panel of the U.S. Court of Appeals for the Federal Circuit will consider Adapt’s appeal Monday.”